Outcomes of poor peripheral blood stem cell mobilizers with multiple myeloma at the first mobilization: A multicenter retrospective study in Japan

Autor: Yurie Miyamoto‐Nagai, Naoya Mimura, Nobuhiro Tsukada, Nobuyuki Aotsuka, Masaki Ri, Yuna Katsuoka, Toshio Wakayama, Rikio Suzuki, Yoriko Harazaki, Morio Matsumoto, Kyoya Kumagai, Takaaki Miyake, Shuji Ozaki, Katsuhiro Shono, Hiroaki Tanaka, Arika Shimura, Yoshiaki Kuroda, Kazutaka Sunami, Kazuhito Suzuki, Takeshi Yamashita, Kazuyuki Shimizu, Hirokazu Murakami, Masahiro Abe, Chiaki Nakaseko, Emiko Sakaida

Publikováno v: eJHaem, Vol 3, Iss 3, Pp 838-848 (2022)

Abstract Autologous stem cell transplantation (ASCT) remains an important therapeutic strategy for multiple myeloma; however, a proportion of patients fail to mobilize a sufficient number of peripheral blood stem cells (PBSCs) to proceed to ASCT. In

Externí odkaz: https://doaj.org/article/1fbaa13893404ef3bdca3b5fe8e6800d

A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B‐cell lymphoma

Autor: Yasunori Ueda, Noriko Fukuhara, Shinya Rai, Kenichi Ishizawa, Tomohisa Saito, Koji Izutsu, Yasuhito Terui, Hirohiko Shibayama, Kazuhito Yamamoto, Hideki Goto, Motoko Yamaguchi, Takayuki Ishikawa, Atsuko Kawasaki, Junya Kuroda, Youko Suehiro, Kyoya Kumagai, Ken Ohmine, Jun Takizawa, Misato Hashizume, Nobuhiro Kanemura, Koji Kato

Publikováno v: Cancer Science

Polatuzumab vedotin (pola) is a CD79b‐targeted antibody‐drug conjugate delivering a potent antimitotic agent (monomethyl auristatin E) to B cells. This was an open‐label, single‐arm study of pola 1.8 mg/kg, bendamustine 90 mg/m2, rituximab 37

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f61833e55baad8f4a7a85afdc11c3dcc
http://europepmc.org/articles/PMC8253277

Prophylactic Antiemetics for Haematological Malignancies: Prospective Nationwide Survey Subset Analysis in Japan

Autor: Kyoya Kumagai, Tsutomu Takahashi, Moritaka Gotoh, Yasuhito Nanya, Toshihiro Miyamoto, Mototsugu Shimokawa, Yasushi Takamatsu, Itaru Matsumura, Naoki Kurita, Kiyohiko Hatake, Isao Yoshida, Keisuke Aiba, Kenichi Ishizawa, Noriko Usui, Kazuo Tamura, Tadahiko Igarashi

Publikováno v: In Vivo. 33:1355-1362

Background/aim Although neurokinin-1 receptor antagonists are approved chemotherapy drugs in Japan, no nationwide surveys have been performed to validate chemotherapy-induced nausea and vomiting (CINV) guidelines in clinical practice. This study eval

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6345c8af8e9394ddbf6a48280eb61ca
https://doi.org/10.21873/invivo.11611

Correction to: Plerixafor for mobilization and collection of haematopoietic stem cells for autologous transplantation in Japanese patients with non-Hodgkin lymphoma: a randomized phase 2 study

Autor: Kyoya Kumagai, Toshihiro Miyamoto, Kenshi Suzuki, Isamu Sugiura, Takaaki Ono, Yasunori Ueda, Tadahiko Igarashi, Tsutomu Sato, Michihiro Uchiyama, Yoshinori Sunaga, Takayuki Ishikawa, Toru Kiguchi, Toru Sasaki, Kosei Matsue

Publikováno v: International journal of hematology. 108(5)

The affiliation of the last author, Kenshi Suzuki has been incorrectly published in the original publication of the article. The correct affiliation is provided in this correction.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d757386d0f26a3af619cc8b5bac9466
https://pubmed.ncbi.nlm.nih.gov/30043330

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Autor: Judith Trotman, Sally F Barrington, David Belada, Michel Meignan, Robert MacEwan, Carolyn Owen, Václav Ptáčník, András Rosta, Günter R Fingerle-Rowson, Jiawen Zhu, Tina Nielsen, Deniz Sahin, Wolfgang Hiddemann, Robert E Marcus, Andrew Davies, Mark Hertzberg, Andrew Grigg, Paul Cannell, Hang Quach, Stephen Opat, Constantine Tam, Paula Marlton, Ann Janssens, Fritz Offner, Koen Van eygen, Randeep Sangha, Pam Mckay, Jonathan Wilson, Richard Van Der Jagt, Daryl Roitman, Marek Trneny, Jiri Mayer, Katell Le Du, Philippe Solal-Celigny, Guillaume Cartron, Charles Foussard, Norbert Frickhofen, Peter Schmidt, Ullrich Graeven, Tobias Gaska, Rudolf Schlag, Martin Sökler, Gabriele Prange-Krex, Axel Florschütz, Hans-Walter Lindemann, Christoph Schimmelpfennig, Solveig Tonndorf, Mathias Hänel, Georg Hess, Enrico Schalk, Heiko Hütten, Gottfried Doelken, Michael Pfreundschuh, Ulrich Keller, Michael Herold, Roswitha Forstpointner, Ursula Vehling-Kaiser, Martin Hoffmann, Zita Borbenyi, Miklos Udvardy, Judit Demeter, Alessandro Rambaldi, Enrica Morra, Federico Massimo, Ignazio Majolino, Monica Balzarotti, Gianpietro Semenzato, Miguel Angel Canales Albendea, Francisco Javier Peñalver Parraga, Alfonso Soler Campos, Juan Manuel Sancho Cia, Jose Antonio Marquez Navarro, Carlos Grande Garcia, Herman Nilsson-Ehle, Helen Mccarthy, Chris Pocock, Shalal Sadullah, Ram Malladi, John Radford, Ed Kanfer, Anton Kruger, Dominic Culligan, Martin Dyer, Ruth Pettengell, John Seymour, John Gribben, Saad Al-Ismail, Faris Al-Refaie, Norbert Blesing, Christopher Macnamara, Ann O'callaghan, Andrew Haynes, George Follows, Roderick Johnson, David Cunningham, Kristian Bowles, Graham Collins, Eve Gallop-Evans, Stephen Robinson, Chezhian Subash, James Bailey, Viran Holden, Jeffrey Neidhart, Moacyr De Oliveira, Haluk Tezcan, Kevin Kim, Suman Kambhampati, Keith Lanier, John Mcclean, Kensei Tobinai, Kiyohiko Hatake, Michinori Ogura, Toshiki Uchida, Kiyoshi Ando, Tomohiro Kinoshita, Thomas Höhler, Heribert Stauder, Andreas Kirsch, Michael Koenigsmann, Stephan Kremers, Thomas Illmer, Mathias Witzens-Harig, Paul La Roseé, Jan Dürig, Michael Kneba, Manfred Hensel, Stefan Fuxius, Lothar Bergmann, Kai Hübel, Christian Buske, Reinhard Marks, Gerald Wulf, Christian Lerchenmueller, Rudolf Schmits, Mark Reinwald, Eva Lengfelder, Fiona Scott, Takaaki Chou, Masafumi Taniwaki, Isao Yoshida, Kenichi Ishizawa, Naokuni Uike, Nobuhiko Uoshima, Yuri Kamitsuji, Shinsuke Iida, Ken Ohmine, Kisato Nosaka, Kazuhiko Ide, Takayuki Ishikawa, Pierre Desjardins, Nicholas Finn, Jun Zhu, Wei Li, Li Yu, Hanyun Ren, Yuan Kai Shi, Gang Wu, Xiaonan Hong, Qingyuan Zhang, Jifeng Feng, Rong Zhan, Tongyu Lin, Sirpa Leppa, Regis Costello, Adrian Tempescul, Laurence Sanhes, Olivier Tournilhac, Heinz Kirchen, Holger Hebart, Rudolf Weide, Kathleen Jentsch-Ullrich, Irit Avivi, Arnon Nagler, Ronit Gurion, Ofer Shpilberg, Pietro Leoni, Luca Baldini, Olga Samoylova, Alexandr Myasnikov, Tran-Der Tan, Hung Chang, Kyoya Kumagai, Norifumi Tsukamoto, Kunihiro Tsukasaki, Patrick Beatty, Noriko Usui, Koji Izutsu, Tohru Murayama, Tatsuo Ichinohe, Kohmei Kubo, Fumihiro Ishida, J. Thaddeus Beck, Frank Griesinger, Dzhelil Osmanov, Shaker Dakhil, Aline Clavert, Dai Maruyama, Yasuhito Terui, Kazuhito Yamamoto, Ekkehard Eigendorff, Tsutomu Kobayashi, Satoshi Ichikawa, Ilseung Choi, Katsuya Wada, Yoshitaka Kikukawa, Masao Matsuoka, Takayuki Yoshino, Yosuke Minami

Publikováno v: Lancet Oncology
Lancet Oncology, Elsevier, 2018, 19 (11), pp.1530--1542. ⟨10.1016/S1470-2045(18)30618-1⟩
Trotman, J, Barrington, S F, Belada, D, Meignan, M, MacEwan, R, Owen, C, Ptáčník, V, Rosta, A, Fingerle-Rowson, G R, Zhu, J, Nielsen, T, Sahin, D, Hiddemann, W, Marcus, R E, Davies, A 2018, ' Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM) : secondary analysis of a randomised, phase 3 trial ', The Lancet Oncology, vol. 19, no. 11, pp. 1530-1542 . https://doi.org/10.1016/S1470-2045(18)30618-1
PET investigators from the GALLIUM study 2018, ' Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM) : secondary analysis of a randomised, phase 3 trial ', The Lancet Oncology, vol. 19, no. 11, pp. 1530-1542 . https://doi.org/10.1016/S1470-2045(18)30618-1

BACKGROUND: Initial results from the ongoing GALLIUM trial have shown that patients with follicular lymphoma have a longer progression-free survival after first-line immunochemotherapy with obinutuzumab than with rituximab. The aim of this secondary

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6d3a2d8bd363c591c6c68c64af82f42
https://pubmed.ncbi.nlm.nih.gov/31047802